Zobrazeno 1 - 10
of 279
pro vyhledávání: '"Simon F Lacey"'
Autor:
Rachel S Leibman, Max W Richardson, Christoph T Ellebrecht, Colby R Maldini, Joshua A Glover, Anthony J Secreto, Irina Kulikovskaya, Simon F Lacey, Sarah R Akkina, Yanjie Yi, Farida Shaheen, Jianbin Wang, Keith A Dufendach, Michael C Holmes, Ronald G Collman, Aimee S Payne, James L Riley
Publikováno v:
PLoS Pathogens, Vol 13, Iss 10, p e1006613 (2017)
HIV is adept at avoiding naturally generated T cell responses; therefore, there is a need to develop HIV-specific T cells with greater potency for use in HIV cure strategies. Starting with a CD4-based chimeric antigen receptor (CAR) that was previous
Externí odkaz:
https://doaj.org/article/942f579e40144a97893d9fb154526278
Autor:
Oliver Y. Tang, Lifeng Tian, Todd Yoder, Rong Xu, Irina Kulikovskaya, Minnal Gupta, Jan Joseph Melenhorst, Simon F. Lacey, Donald M. O’Rourke, Zev A. Binder
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The epidermal growth factor receptor variant III (EGFRvIII) has been investigated as a therapeutic target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma. Earlier research demonstrated that phenotypic and genotypic characteristics
Externí odkaz:
https://doaj.org/article/1ad163a08eb94e1897776463e363af54
Autor:
Adam D. Cohen, Alfred L. Garfall, Ahmet Dogan, Simon F. Lacey, Chris Martin, Nikoletta Lendvai, Dan T. Vogl, Matthew Spear, Alexander M. Lesokhin
Publikováno v:
Blood Advances, Vol 3, Iss 16, Pp 2487-2490 (2019)
Externí odkaz:
https://doaj.org/article/5edb8c5900584745961e8dc35d27bd8d
Autor:
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey
Publikováno v:
Engineering, Vol 5, Iss 1, Pp 140-149 (2019)
Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life. Unlike chemical compounds and proteins,
Externí odkaz:
https://doaj.org/article/efc3dde1d79240f08fcbd718400b5236
Autor:
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, Robert Orlowski, Ravi K. Amaravadi, Lynn M. Schuchter, Paul Zhang, Julia Tchou, Tina Matlawski, Amanda Cervini, Joanne Shea, Joan Gilmore, Lester Lledo, Karen Dengel, Amy Marshall, E. John Wherry, Gerald P. Linette, Andrea Brennan, Vanessa Gonzalez, Irina Kulikovskaya, Simon F. Lacey, Gabriela Plesa, Carl H. June, Robert H. Vonderheide, Tara C. Mitchell
Publikováno v:
Cancer Research Communications. 3:821-829
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0368480eb756635728b862b5d77d081c
https://doi.org/10.1158/2767-9764.crc-22-0486
https://doi.org/10.1158/2767-9764.crc-22-0486
Autor:
Mireia Uribe-Herranz, Silvia Beghi, Marco Ruella, Kalpana Parvathaneni, Silvano Salaris, Nektarios Kostopoulos, Subin S. George, Stefano Pierini, Elisavet Krimitza, Francesca Costabile, Guido Ghilardi, Kimberly V. Amelsberg, Yong Gu Lee, Raymone Pajarillo, Caroline Markmann, Bevin McGettigan-Croce, Divyansh Agarwal, Noelle Frey, Simon F. Lacey, John Scholler, Khatuna Gabunia, Gary Wu, Elise Chong, David L. Porter, Carl H. June, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene
Publikováno v:
Molecular Therapy. 31:686-700
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f452ab38962928b51e549d95a9be6f55
https://doi.org/10.1016/j.ymthe.2023.01.012
https://doi.org/10.1016/j.ymthe.2023.01.012
Autor:
Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei-Ting Hwang, Dan T. Vogl, Adam J. Waxman, Simon F. Lacey, Vanessa E. Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer
Publikováno v:
Blood Cancer Discovery. 4:118-133
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af15a4e58dc3d2eade0573800002170e
https://doi.org/10.1158/2643-3230.bcd-22-0074
https://doi.org/10.1158/2643-3230.bcd-22-0074
Autor:
Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav V. Dhodapkar
Publikováno v:
Blood Cancer Discovery. 3:490-501
Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most patients experience recurrent disease. We combined several high-dimensional approaches to study tumor/immune cells in the tumor microenvironment (TME) of myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a8f4143080e2a873e434dc2b50b1a43
https://doi.org/10.1158/2643-3230.bcd-22-0018
https://doi.org/10.1158/2643-3230.bcd-22-0018
Autor:
Tara C. Mitchell, Robert H. Vonderheide, Carl H. June, Gabriela Plesa, Simon F. Lacey, Irina Kulikovskaya, Vanessa Gonzalez, Andrea Brennan, Gerald P. Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K. Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D. Shah
Study procedures. Participant study procedures including cell collection/manufacturing timeline as well as infusion schedule from eligibility confirmation onward.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e40732ed1e1a9fe11f9fc7a214caad
https://doi.org/10.1158/2767-9764.22787708.v1
https://doi.org/10.1158/2767-9764.22787708.v1
Autor:
Tara C. Mitchell, Robert H. Vonderheide, Carl H. June, Gabriela Plesa, Simon F. Lacey, Irina Kulikovskaya, Vanessa Gonzalez, Andrea Brennan, Gerald P. Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K. Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D. Shah
Purpose:Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7637614404a385b771276bf3e332121
https://doi.org/10.1158/2767-9764.c.6547846
https://doi.org/10.1158/2767-9764.c.6547846